ChemicalBook > CAS DataBase List > Adebrelimab
Adebrelimab
- Product Name
- Adebrelimab
- CAS No.
- 2247114-85-6
- Chemical Name
- Adebrelimab
- Synonyms
- Adebrelimab;Adebrelimab (anti-PD-L1);Research Grade Adebrelimab;Research Grade Adebrelimab (DHJ70108)
- CBNumber
- CB210616943
- Formula Weight
- 0
- MOL File
- Mol file
More
Less
Adebrelimab Property
- form
- Liquid
- color
- Colorless to light yellow
More
Less
Adebrelimab Chemical Properties,Usage,Production
Uses
Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC)[1][2].
in vivo
Adebrelimab (SHR-1316; 200 μg; three times a week; for 21 days) shows inhibition effects on tumor growth[1].
| Animal Model: | Pathogen free (SPF) BALB/c nude female mice (aged 5-6 weeks) injected with SK-BR-3 cells[1] |
| Dosage: | 200 μg |
| Administration: | Three times a week; for 21 days |
| Result: | Significantly inhibited tumor growth. |
References
[1] Zhiwei Liu, et al. The Synergistic Effects of Pyrotinib and SHR-1316 on HER2-positve breast cancer. Research Square. May 19th, 2022.
[2] Wanpu Yan, et al. Adebrelimab (SHR-1316) in combination with chemotherapy as perioperative treatment in patients with resectable stage II-III NSCLC: an open-label, multicenter, phase 1b trial. J Thorac Oncol. 2022 Sep 30;S1556-0864(22)01822-6. DOI:10.1016/j.jtho.2022.09.222
Adebrelimab Preparation Products And Raw materials
Raw materials
Preparation Products
More
Less
Adebrelimab Suppliers
- Tel
- +1-781-999-5354;
- support@targetmol.com
- Country
- United States
- ProdList
- 39035
- Advantage
- 58
2247114-85-6, AdebrelimabRelated Search:
Zanidatamab
Teclistamab
Dusigitumab
Spartalizumab
Iparomlimab
Elgemtumab
Maftivimab
Pidilizumab
Socazolimab
Osocimab